분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-01-02 19:04:30 , Hit : 992
 Off Switch Found for Common Version of the CRISPR-Cas9 System

GEN News Highlights

December 29, 2016

Shouldn’t a better mousetrap have a better off switch? That’s the question posed by researchers at the University of California, San Francisco (UCSF), who are working to make molecular biology’s better mousetrap—the CRISPR-Cas9 gene-editing system—even better. Although CRISPR-Cas9 is a tremendously exciting tool, one that can target selected genomic sites, it isn’t exactly glitch-free. It can snip at genomic sites that should be left alone, and may be more apt to meddle where it shouldn’t, given its tendency to loiter, remaining active even after it should retire.

But the CRISPR-Cas9 system can be deactivated. We know this because it doesn’t always work in its natural element, bacteria. While CRISPR-Cas9 serves as an immune system for bacteria, it is sometimes circumvented by viruses it ought to eliminate.

What do viruses know that we don’t? If only we knew, we could turn off CRISPR-Cas9 at will, preventing off-target effects and hastening CRISPR-Cas9 applications in the clinic.

Hoping to learn from the evolutionary struggle between bacteria and viruses, UCSF scientists decided to take a close look at viruses that are capable of frustrating CRISPR-Cas9. The scientists reasoned that they should be able to identify bacteria with inactivated CRISPR systems by looking for evidence of so-called "self-targeting"—bacterial strains where some virus had successfully gotten through the Cas9 blockade and inserted its genes into the bacterial genome. That is, viral DNA appearing both in a bacteria’s CRISPR array as well as elsewhere in its genome could be a sign of self-targeting.

The UCSF team hypothesized that CRISPR-defeating viruses must encode some anti-CRISPR agent, or else Cas9 would kill the bacteria by cutting its own genome where the viral DNA had been inserted. To find such agents, the team searched cas9-containing bacterial genomes for the co-existence of a CRISPR spacer and its target, a potential indicator for CRISPR inhibition.

The results of this investigation appeared December 29 in the journal Cell, in an article entitled, “Inhibition of CRISPR-Cas9 with Bacteriophage Proteins.”

“This analysis led to the discovery of four unique type II-A CRISPR-Cas9 inhibitor proteins encoded by Listeria monocytogenes prophages,” wrote the study’s authors. “More than half of L. monocytogenes strains with cas9 contain at least one prophage-encoded inhibitor, suggesting widespread CRISPR-Cas9 inactivation. Two of these inhibitors also blocked the widely used Streptococcus pyogenes Cas9 when assayed in Escherichia coli and human cells.”

The two inhibitors capable of blocking Streptococcus pyogenes Cas9, or SpyCas9, are called AcrIIA2 and AcrIIA4. Because SpyCas9 is the Cas9 variant that is now used by most labs around the world, AcrIIA2 and AcrIIA4 may prove to be an especially attractive anti-CRISPR-Cas9 tool. Other anti-CRISPR-Cas9 tools have been introduced, but they work against less common Cas9 variants.

The current study was led by Benjamin Rauch, Ph.D., a post-doctoral researcher in the laboratory of Joseph Bondy-Denomy, Ph.D., who is a UCSF Sandler Faculty Fellow in the Department of Microbiology and Immunology.

"The next step is to show in human cells that using these inhibitors can actually improve the precision of gene editing by reducing off-target effects," said Dr. Rauch. "We also want to understand exactly how the inhibitor proteins block Cas9's gene targeting abilities, and continue the search for more and better CRISPR inhibitors in other bacteria."

Drs. Rauch and Bondy-Denomy believe the ability to deactivate SpyCas9 will make CRISPR-based gene editing much safer and more precise by resolving the ongoing problem of unintended "off-target" gene modifications, which become more likely the longer the CRISPR gene editing machinery remains active in target cells.

The discovery could also be a boon for scientists using newer CRISPR techniques—such as CRISPR interference and CRISPR activation—which use Cas9 not to modify gene sequences but to precisely tune their activity up and down. Using anti-CRISPR proteins, researchers could boost or block gene activity temporarily, potentially even synchronizing choreographed bursts of activity from sets of interconnected genes across the genome, which could be key to studying and treating complex, multi-gene diseases.

CRISPR inhibitors could also prove to be a valuable safeguard, the researchers say, enabling scientists to quickly halt any application of CRISPR gene editing outside the lab.

"Researchers and the public are reasonably concerned about CRISPR being so powerful that it potentially gets put to dangerous uses," noted Dr. Bondy-Denomy. "These inhibitors provide a mechanism to block nefarious or out-of-control CRISPR applications, making it safer to explore all the ways this technology can be used to help people."








1167   Scientists unveil CRISPR-based diagnostic platform  이성욱 2017/04/14 813
1166   [사이언스 카페] 美 FDA, 민간업체의 '개인용 유전자 검사' 첫 허용  이성욱 2017/04/10 795
1165   암 전이에 핵심 역할하는 줄기세포 찾았다  이성욱 2017/04/03 1163
1164   ‘단세포 인공생명체’ 눈앞에 성큼  이성욱 2017/03/11 793
1163   Beyond CRISPR Cuts: Five Complements To Cas9  이성욱 2017/02/24 986
1162   Smallest CRISPR So Far Comes from Food Poisoning Bacteria  이성욱 2017/02/24 923
1161   CRISPR Turbocharges CAR T Cells, Boosts Cancer Immunotherapy  이성욱 2017/02/24 1289
1160   [바이오토픽] 브로드 연구소, 열띤 CRISPR 특허전쟁에서 승리  이성욱 2017/02/16 1057
1159   Judges Side with Broad Institute in CRISPR Patent Dispute  이성욱 2017/02/16 954
1158   미국 과학·공학·의학 아카데미, 「GM 베이비」의 진행방향에 대한 윤곽 발표  이성욱 2017/02/16 1070
1157   Nano-CRISPR Packages Attain 90% Delivery Rate with Engineered Cas9  이성욱 2017/02/09 1327
1156   유전자 치료로 청력 되살린다  이성욱 2017/02/08 1347
1155   바이러스들도 서로 소통..“상황에 따라 감염방식 결정”  이성욱 2017/01/24 1131
1154   Oligonucleotide Therapeutics Near Approval  이성욱 2017/01/10 1167
  Off Switch Found for Common Version of the CRISPR-Cas9 System  이성욱 2017/01/02 992
1152   Editas Expands CRISPR Capabilities through New Technology Licensing  이성욱 2016/12/22 819
1151   RNA Modification Helps Drosophila Straighten Up and Fly Right  이성욱 2016/12/10 885
1150   Anti-CRISPR Protein Is Gene Editing “Off-Switch”  이성욱 2016/12/10 1890
1149   Could Gene Therapy Work for Alzheimer’s Disease?  이성욱 2016/10/12 1156
1148   EU, 2번째 유전자치료제 ‘스트림벨리스’ 승인  이성욱 2016/09/05 1145

[1][2][3][4][5] 6 [7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN